Skip to content
CheckOrphan
  • Home
  • About Us
  • Team
  • Log In
  • News
    • All News
    • Finance
    • Treatment
    • People
  • Videos
  • Treatments
  • Clinical Trials
  • Access Programs
    • All Access Programs
  • Diseases
  • Events
  • Networks
  • Research
Main Menu

Subscribe for Free Newsletter

Email *

Type *

* Required Field
Email Marketing Services by Benchmark

Generate RSS

  1. Home
  2. /
  3. Treatment
  4. /
  5. fenfluramine HCI

fenfluramine HCI

April 12, 2017
fenfluramine HCI
Trade Name Brabafen
Orphan Indication Dravet Syndrome
USA Market Approval USA
USA Designation Date 2013-12-20 00:00:00
Sponsor Zogenix, Inc.;5858 Horton Street, Suite 455, RG9 2LT;Emeryville, California
Related Access Program
M. Scott Perry – Dravet Syndrome M. Scott Perry – Dravet Syndrome University of Colorado, Denver – Dravet Syndrome Children’s Hospital Medical Center, Cincinnati – Dravet Syndrome

Free Newsletter

Related Treatment

  • Cholesterol 24S-hydroxylase inhibitor
  • Clemizole
  • Huperzine A
  • Synthetic, single stranded, fully phosphorothioated 2�-OMethyl-RNA a
  • 26 base synthetic single-stranded fully phosphorothioated 2′-O-m
More Treatment
pw

About CheckOrphan

CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected diseases. CheckOrphan offers users an interactive and dynamic platform for all these diseases. This strategy allows visitors to be updated daily on all the latest news and interact with people internationally. This is essential, because due to the nature of these diseases, there is not a large concentration of individuals within any given proximity.
Click here to know more About Us

Your email is important to us

Each email is sent to a CheckOrphan staff member and will be answered. We only use a contact form to avoid spam.

    Copyright © 2022 CheckOrphan.
    Developed by: Gonza.io logo Powered by: Cloudscale logo